Browsing Tag
Brandon Capital
2 posts
Could monthly treatment replace burdensome peanut allergy dosing? Aravax may soon have an answer
Aravax gains FDA Fast Track status for PVX108 as Phase 2 peanut allergy data approach and preparations for a possible Phase 3 program advance.
August 5, 2026
AdvanCell strengthens cancer drug pipeline with $112m Series C funding
AdvanCell, a clinical-stage radiopharmaceutical company specializing in targeted alpha therapy, has successfully completed an oversubscribed $112 million Series…
February 4, 2025